Open AccessSofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over
Author(s) -
Hideyuki Tamai,
Naoki Shingaki,
Yoshiyuki Ida,
Ryo Shimizu,
Shuya Maeshima,
Junpei Okamura,
Akira Kawashima,
Taisei Nakao,
Takeshi Hara,
Hiroyoshi Matsutani,
Izumi Nishikawa,
Katsuhiko Higashi
Publication year - 2020
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v12.i9.672
Subject(s) - medicine , ribavirin , sofosbuvir , hepatocellular carcinoma , gastroenterology , hepatitis c virus , hepatitis c , cohort , surgery , virology , virus
Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials.